Dihexa: cognitive neurotrophin research under scrutiny
Why hepatocyte growth factor / synaptic research does not justify memory or focus promises.
Educational information only — not medical advice. This page does not diagnose conditions, recommend treatment, or replace care from a qualified clinician. The Peptide Center uses an evidence-first editorial process: regulatory sources, trial registries, and peer-reviewed research take priority; uncertainty is stated rather than filled with promises.
Dihexa is discussed in cognitive neuroscience research related to hepatocyte growth factor (HGF) signaling and synaptic plasticity. The research is scientifically interesting and also contested in its translation to humans. Bold cognitive claims outpace the reliable evidence base for marketed products.
References
- Therapeutic peptides: recent advances in discovery, synthesis, and clinical applications. Signal Transduction and Targeted Therapy, 2022
- ClinicalTrials.gov: Learn about studies
- FDA: The drug development process
Related resources
Continue with curated, same-topic resources from the published library. These links are educational references, not treatment recommendations.
How to read a peptide study without overclaiming
A practical guide to research stage, controls, endpoints, uncertainty, and applicability.
Open resourceArticleA clinical-trial record is not proof that a peptide works
What a trial registry can tell you, what it cannot, and how to avoid overreading a study status.
Open resourceArticleSemax: cognitive research without overclaiming
How to read semax literature and regional regulatory context without turning a mechanism into a treatment promise.
Open resourceArticleDSIP: sleep-peptide research in context
Why delta sleep-inducing peptide research is not the same as a proven sleep treatment.
Open resource